1-3 of 3
Leslie Pettiford, RN
Close
Sort by
Journal Articles

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

Shannon Somer Stockton, BA, Leslie Pettiford, RN, MS, CCRC, Christina Cline, RN, BSN, David Chaplin, PhD, Jack W Hsu, John R. Wingard, MD, Christopher R. Cogle, MD
Journal: Blood
Blood (2015) 126 (23): 4936.
https://doi.org/10.1182/blood.V126.23.4936.4936
Published: 2015
Journal Articles

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Daniel Turner, BS, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Raphael C Bosse, BS, Dai Chaplin, PhD, Jack W. Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, Maxim Norkin, MD, PhD, John R Wingard, MD, Christopher R Cogle, MD
Journal: Blood
Blood (2013) 122 (21): 1463.
https://doi.org/10.1182/blood.V122.21.1463.1463
Published: 2013
Journal Articles

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R Cogle, MD, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Maxim Norkin, MD, PhD, David Chaplin, PhD, Jai Balkissoon, MD, Jack W Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, John R Wingard, MD
Journal: Blood
Blood (2012) 120 (21): 4335.
https://doi.org/10.1182/blood.V120.21.4335.4335
Published: 2012